Ibandronic acid

DRUG3 trials

Sponsors

University of Turku, Clinic of Endocrinology and Metabolic Disorders, Macedonia, Azienda Ospedaliero-Universitaria Careggi

Conditions

Breast CancerOsteoporosis

Phase 2

Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients

University of TurkuBreast Cancer

Start: 2006-10-31Target: 60Updated: 2006-12-04

Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors

CompletedNCT02616744

Azienda Ospedaliero-Universitaria CareggiBreast Cancer

Start: 2011-01-31End: 2016-05-31Updated: 2019-10-22

Unknown Phase

Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis

CompletedNCT02271204

Clinic of Endocrinology and Metabolic Disorders, MacedoniaOsteoporosis

Start: 2009-03-31End: 2014-04-30Updated: 2014-10-22

Related Papers

Abstract P4-16-04: Oral ibandronate for osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: secondary 5-year survival outcomes analysis of the single-center phase 2 BONADIUV trial

Cancer Research2019-02-151 citations

Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.

2019-01-1415 citations

Abstract P2-09-12: A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADIUV trial

Cancer Research2017-02-15

BONADIUV trial: A single blind, randomized placebo controlled phase II study using oral ibandronate for osteopenic women receiving adjuvant aromatase inhibitors: Final safety analysis.

Journal of Clinical Oncology2016-05-203 citations